Revolution Medicines, Inc.
RVMD
Updated: 23/09/2026, 15:04:23
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
No summaries found.
- Share price
- $192.86
- Market cap
- $41.00B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Mark A. Goldsmith
- Employees
- 883
- IPO date
- 13/02/2020
- Beta
- 1.406
- Last dividend
- $0.00
- Day range
- $191.22 – $195.28
- 52-week range
- $42.18 – $224.31
- 1-day performance
- 0.05%
- 1-year performance
- 357.23%
- Current drawdown (1Y)
- -14.02%
- CIK
- 0001628171
- CUSIP
- 76155X100
- ISIN
- US76155X1000
- Created
- 07/12/2025, 14:04:21
- Last update
- 23/09/2026, 15:04:23
Track Revolution Medicines, Inc. with an AI analyst
See which prediction-market events move RVMD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Seeking Alpha • STOCK • 13/06/2026, 07:04:54
RVMD Pancreatic Cancer Breakthrough: Target Hike to $195
Market Data • Market Data • 01/06/2026, 18:12:19
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
Seeking Alpha • STOCK • 01/06/2026, 14:14:05
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Zacks Investment Research • STOCK • 01/06/2026, 12:16:24
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Benzinga • STOCK • 01/06/2026, 00:43:12
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
GlobeNewsWire • STOCK • 31/05/2026, 10:06:00
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
GlobeNewsWire • STOCK • 21/05/2026, 18:05:00
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
Reuters • STOCK • 14/05/2026, 08:04:56
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Zacks Investment Research • STOCK • 07/05/2026, 15:50:13
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
GlobeNewsWire • STOCK • 06/05/2026, 20:00:00
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
GlobeNewsWire • STOCK • 06/05/2026, 18:02:00
There's a Revolution in Cancer. But Can Big Pharma Afford It?
WSJ • STOCK • 28/04/2026, 07:30:00